Early apoptosis in different models of cardiac hypertrophy induced by high renin-angiotensin system activity involves CaMKII

J. Omar Velez Rueda, Julieta Palomeque, and Alicia Mattiazzi

Centro de Investigaciones Cardiovasculares, Consejo Nacional de Investigaciones Científicas y Técnicas-La Plata, Facultad de Medicina, Universidad Nacional de La Plata, La Plata, Argentina

Submitted 8 November 2011; accepted in final form 3 April 2012

Rueda JO, Palomeque J, Mattiazzi A. Early apoptosis in different models of cardiac hypertrophy induced by high renin-angiotensin system activity involves CaMKII. J Appl Physiol 112: 2110–2120, 2012. First published April 5, 2012; doi:10.1152/japplphysiol.01383.2011.—The objective of this study was to establish whether 1) hyperactivity of renin-angiotensin-aldosterone system (RAAS) produces apoptosis in early stages of cardiac disease; and 2) Ca\(^{2+}\)-calmodulin-dependent protein kinase II (CaMKII) is involved in these apoptotic events. Two models of hypertrophy were used at an early stage of cardiac disease: spontaneously hypertensive rats (SHR) and isoproterenol-treated rats (Iso-rats). At 4 mo, SHR showed blood pressure, aldosterone serum levels, used as RAAS activity index, and left ventricular mass index, used as hypertrophy index, above control values by 28.2 ± 2.6 ± 14.1 ± 14.1 above control). Similar results were observed in 4-mo-old Iso-rats. Cardiac function studied by echocardiography remained unaltered in all groups. Enalapril treatment significantly prevented hypertrophy, apoptosis, and CaMKII activity. Moreover, intracellular Ca\(^{2+}\) handling in isolated myocytes was similar between SHR, Iso-rats, and their aged-matched controls. However, SHR and Iso-rats showed a significant increase in superoxide anion generation (lucigenin) and lipid peroxidation (thiobarbituric acid reactive substance). In transgenic mice with targeted cardiomyocyte expression of a CaMKII inhibitory peptide (AC3-I) or a scrambled control peptide (AC3-C), Iso treatment increased thiorbarbituric acid reactive substance associated with an enhancement of CaMKII activity with respect to age-matched controls (phosphorylated-CaMKII, 98.7 ± 14.1 above control). Similar results were observed in 4-mo-old Iso-rats. Cardiac function studied by echocardiography remained unaltered in all groups. Enalapril treatment significantly prevented hypertrophy, apoptosis, and CaMKII activity. Moreover, intracellular Ca\(^{2+}\) handling in isolated myocytes was similar between SHR, Iso-rats, and their aged-matched controls. However, SHR and Iso-rats showed a significant increase in superoxide anion generation (lucigenin) and lipid peroxidation (thiobarbituric acid reactive substance). In transgenic mice with targeted cardiomyocyte expression of a CaMKII inhibitory peptide (AC3-I) or a scrambled control peptide (AC3-C), Iso treatment increased thiorbarbituric acid reactive substance in both strains, whereas it increased CaMKII activity and apoptosis only in AC3-C mice. Endogenous increases in RAAS activity induce ROS and CaMKII-dependent apoptosis in vivo. CaMKII activation could not be associated with intracellular Ca\(^{2+}\) increments and was directly related to the increase in oxidative stress.

angiotensin II; Ca\(^{2+}\)-calmodulin-dependent protein kinase II; reactive oxygen species; hypertrophy; apoptosis

EXPERIMENTAL EVIDENCE INDICATES that a critical factor in the transition from compensated to noncompensated cardiac hypertrophy is myocyte cell loss by apoptosis and necrosis (42). The circulating levels of angiotensin II (ANG II) are increased in heart failure and may constitute one of the major causes of cell death in this transition (27). Moreover, activation of the multifunctional Ca\(^{2+}\)-calmodulin protein kinase II (CaMKII), which \(\delta\)-isoform is largely predominant in mammalian myocardium (46), is a typical finding in heart failure from different etiologies. Activation of this kinase also constitutes a main step in the signaling cascade that leads to apoptosis following several cardiac insults, like reperfusion injury (39), ionomycin, high extracellular K\(^+\) concentration, intracellular acidosis, and oxidative stress (28, 32, 47). Furthermore, intracellular reactive oxygen species (ROS) levels increase dramatically in models of structural heart disease (18), particularly those initiated by ANG II (35). In recent in vitro experiments, our laboratory described an apoptotic pathway that involves increases in ROS produced by ANG II and activation of CaMKII (28). Exogenous ANG II administration has also been linked to CaMKII and apoptosis in vivo (11). Whether these events can also be triggered by exacerbated endogenous ANG II production and which is their impact, if any, on cardiac function, remains unclear.

It has been shown that spontaneously hypertensive rats (SHR), one of the most used models for hypertrophy and heart failure studies, have high activity of the renin-angiotensin-aldosterone system (RAAS) (45) and increased CaMKII expression (17). Hagemann et al. (17) described that CaMKIIβ is overexpressed in hearts from adult SHR. Furthermore, normotensive rats treated with high doses of isoprotanol (Iso), also show high activity of RAAS (16). However, a possible association between endogenous levels of ANG II in different early stage models of exacerbated RAAS activity and CaMKII-induced apoptosis has not been previously studied. Moreover, the functional consequences of RAAS exacerbation in early stages of heart disease are an uncharted territory. Taking advantage of these models, the present experiments were undertaken to investigate the early repercussion of high RAAS activity on CaMKII activation, apoptosis, and cardiac function.

METHODS

Animals and protocols. All procedures followed during this investigation conform to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication no. 85-23, revised 1996), and the experimental protocol was approved by the Animal Welfare Committee of La Plata School of Medicine.

Male SHR and normotensive aged-matched control Wistar rats were used. At 3 mo, a group of SHR was treated with 10 mg·kg\(^{-1}\)·day\(^{-1}\) enalapril, an inhibitor of the angiotensin converting enzyme (ACE), in the drinking water for 1 mo.

Normotensive Wistar rats were treated at 3 mo with two subcutaneous injections of 250 mg/kg Iso, separated by a 24-h interval, according to a previously described protocol (34), to induce cardiac damage (3, 4, 30). Iso solution was prepared with sterile distilled acid water, to prevent Iso oxidation, immediately before injection. Control rats were injected with the solution without the drug. The rats treated with Iso were further randomly assigned to receive enalapril (Ena) (Iso-Ena rats) (at the doses and way mentioned for SHR) or no drug (Iso-rats). An additional group of rats, receiving only Ena (Ena rats), was used as control. All treatments were performed for 1 mo.
Before and after the treatment, the animals were weighed, the systolic blood pressure was measured by the tail-cuff method, and echocardiographic examination was performed. Rats were then killed, the heart was weighed, and the tibia length (TL) was measured. Hearts were assigned for biochemical studies, immunohistochemical staining, ROS production determinations, or myocyte isolation for contractile and intracellular Ca^{2+} concentration ([Ca^{2+}]i) measurements.

Additionally, transgenic mice with cardiomyocyte-delimited transgenic expression of either a CaMKII inhibitory peptide (AC3-I) or a scrambled control peptide (AC3-C) were used. Breeding mates of these mice were generously supplied by Dr. Mark Anderson (University of Iowa) and reproduced and genotyped in our laboratory. The mice were treated as the Iso-rats, i.e., animals were killed 1 mo after injections, and the hearts were used for measuring ROS, CaMKII activity, and apoptosis.

Aldosterone plasma levels. Aldosterone plasma levels were used as an index of ANG II plasma levels (21) and RAAS activity. Blood samples were centrifuged at 13,500 rpm for 15 min, and the plasma was stored at −80°C until analysis. The plasma aldosterone concentration was measured by standard radioimmunoassay method, according to manufacturer instructions.

Echocardiographic examination. Echocardiogram was performed in each rat under light anesthesia (35 mg/kg ip pentobarbital sodium). Cardiac geometry and function were evaluated by two-dimensional M-mode echocardiography with a 7-MHz linear transducer. All measurements, including left ventricular (LV) wall thickness and diastolic dimensions, were performed according to the American Society of Echocardiography method (31). LV mass was calculated as previously described (24).

Myocyte isolation. Rats were anesthetized by intra-abdominal injection of pentobarbital sodium, and myocytes were isolated by enzymatic digestion (29) and kept in a HEPES buffered solution at room temperature (20–22°C), until used.

[Ca^{2+}]i and cell shortening. Isolated myocytes were loaded with fura 2-AM (10 μmol/l for 15 min). [Ca^{2+}]i, was measured with an epifluorescence system (Ion Optix, Milton, MA). Briefly, dye-loaded cells were placed in a chamber on the stage of an inverted microscope (Nikon.TE 2000-U) and continuously superfused with a HEPES.
buffered solution at a constant flow of 1 ml/min at room temperature (20–22°C). Myocytes were stimulated via two-platinum electrodes on either side of the bath at 0.5 Hz. Fura 2 fluorescence was taken as an index of the [Ca\(^{2+}\)]i. Resting cell length and cell shortening were measured by a video-based motion detector (Ion Optix). Fluorescence and cell shortening data were stored for off-line analysis (ION WIZARD fluorescence analysis software).

**Lipid peroxidation.** Lipid peroxidation was determined by measuring the rate of production of thiobarbituric acid reactive substances (TBARS), expressed as nanomoles per milligram protein. Heart homogenates were centrifuged at 2,000 g for 10 min. Supernatants (0.5 ml) were mixed with 1.5 ml trichloroacetic acid (30% wt/vol) and 0.5 ml water, followed by boiling for 15 min. After cooling, absorbance was determined spectrophotometrically at 535 nm, using a ε value of 1.56 × 105 mmol l\(^{-1}\) cm\(^{-1}\) (5).

**Western blot.** Hearts were freeze-clamped and pulverized. Briefly, 0.1 g of tissue was homogenized in four volumes of lysis buffer (in mmol/l, 30 KH2PO4, 25 NaF, 300 sucrose, 0.1 EDTA plus protease inhibitor cocktail). Protein was measured by the Bradford method using BSA as a standard. Lysates (~90 μg of total protein) were separated per gel line in 10% SDS polyacrylamide gel (26) and transferred to polyvinylidene difluoride membranes. Blots were probed overnight with the following antibodies: Bcl-2 (Santa Cruz), Bax (Santa Cruz), caspase-3 (Chemicon), phosphorylated CaMKII (P-CaMKII) (P-P(CaMKII)) 1:1,000 (Abcam), CaMKIIβ 1:1,000 (Santa Cruz), Thr\(^{17}\)-phosphorylated (P-Thr\(^{17}\)) of phospholamban (PLN) (21) 1:1,000 (Santa Cruz), and caspase-3 (Chemicon). Bands were visualized by enhanced chemiluminescence with the BioRad Chemidoc Imaging System. All antibodies were diluted in 5% non-fat milk in TBS, with 0.1% Tween-20.

**Neuroprotective experiments.** SHRs were treated with 10 mg/kg enalapril (Ena) for 8 weeks and were then subjected to the Western blot and immunohistochemical studies.}

---

Table 1. *Echocardiographic parameters from control rats, SHR, and SHR treated with enalapril*

<table>
<thead>
<tr>
<th></th>
<th>Control</th>
<th>SHR</th>
<th>SHR + Ena</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>9</td>
<td>8</td>
<td>6</td>
</tr>
<tr>
<td>LVDD, mm</td>
<td>5.59 ± 0.32</td>
<td>6.44 ± 0.16</td>
<td>6.07 ± 0.11</td>
</tr>
<tr>
<td>STh, mm</td>
<td>1.52 ± 0.03*</td>
<td>1.85 ± 0.03*</td>
<td>1.71 ± 0.02*</td>
</tr>
<tr>
<td>LVPWTh, mm</td>
<td>1.55 ± 0.02*</td>
<td>1.92 ± 0.06*</td>
<td>1.70 ± 0.03*</td>
</tr>
<tr>
<td>ES, %</td>
<td>60.76 ± 0.89</td>
<td>60.87 ± 0.46</td>
<td>61.39 ± 1.34</td>
</tr>
<tr>
<td>MVS, %</td>
<td>30.60 ± 1.51</td>
<td>30.53 ± 0.96</td>
<td>30.66 ± 0.77</td>
</tr>
<tr>
<td>LVMI, mg/g</td>
<td>1.39 ± 0.09*</td>
<td>2.61 ± 0.12*</td>
<td>2.04 ± 0.05*</td>
</tr>
<tr>
<td>LVMI, mg/mm</td>
<td>12.79 ± 1.05*</td>
<td>21.43 ± 1.15*</td>
<td>17.81 ± 0.39*</td>
</tr>
</tbody>
</table>

Values are means ± SE; n, no. of rats. SHR, spontaneously hypertensive rats; LVDD, left ventricular diastolic diameter; STh, septum thickness; LVPWTh, left ventricular posterior wall thickness; ES, endocardial shortening; MVS, midwall ventricular shortening; LVMI, left ventricular mass index. *P < 0.05 vs. all others groups.
ate. One-way ANOVA was used for multigroup comparisons. The Newman-Keuls test was used to examine statistical differences observed with ANOVA. A value of $P < 0.05$ was taken to indicate statistical significance.

RESULTS

High RAAS activity-induced cardiac hypertrophy and apoptosis in SHR is associated with CaMKII activation. Aldosterone plasma levels and blood pressure were significantly increased in 4-mo-old SHR with respect to age-matched normotensive control rats (Fig. 1, A and B). Moreover, Fig. 1, C–G, shows that SHR developed hypertrophy, as indicated by the increase in the heart weight-to-TL ratio (HW/TL), the cross-sectional area of the myocytes and the LV mass index (LVMI) evaluated by echocardiography (see also Table 1). Representative images of echocardiography and LV specimens obtained from each experimental group are shown in the right panels of Fig. 1 (D and F). As shown in the examples of Fig. 1F and Table 1, although hypertrophy is present in SHR (increase in septum thickness, posterior wall thickness, and LVMI), no
Apoptosis in Heart Via RAAS and CaMKII - Rueda JO et al.

A) Graph showing aldosterone plasma levels, blood pressure, HW/TL, and LVM.

B) Images of myocardium sections showing TUNEL and DAPI staining.

C) Graph showing TUNEL positive cells as a percentage of DAPI.

D) Western blots showing protein expression of P-CaMKII, CaMKII, GAPDH, P-Thr17, PLN, Bcl-2, Bax, and Caspase-3.
Table 2. Echocardiographic parameters from control rats, isoproterenol rats, and isoproterenol rats treated with enalapril

<table>
<thead>
<tr>
<th></th>
<th>Wistar</th>
<th>Wistar Isoproterenol</th>
<th>Wistar + Enalapril</th>
<th>Wistar Isoproterenol + Enalapril</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>12</td>
<td>29</td>
<td>4</td>
<td>7</td>
</tr>
<tr>
<td>LVDD, mm</td>
<td>5.20 ± 0.13*</td>
<td>5.81 ± 0.07*</td>
<td>3.72 ± 0.12*</td>
<td>4.43 ± 0.23*</td>
</tr>
<tr>
<td>STh, mm</td>
<td>1.54 ± 0.03‡</td>
<td>1.64 ± 0.02‡</td>
<td>1.26 ± 0.02‡</td>
<td>1.23 ± 0.05‡</td>
</tr>
<tr>
<td>LV PWTh, mm</td>
<td>1.56 ± 0.02‡</td>
<td>1.70 ± 0.02‡</td>
<td>1.24 ± 0.02‡</td>
<td>1.22 ± 0.04‡</td>
</tr>
<tr>
<td>ES, %</td>
<td>60.76 ± 0.70</td>
<td>59.86 ± 0.40</td>
<td>58.98 ± 1.0</td>
<td>58.52 ± 0.86</td>
</tr>
<tr>
<td>MVS, %</td>
<td>30.16 ± 1.32</td>
<td>33.03 ± 0.90</td>
<td>33.1 ± 1.02</td>
<td>34.52 ± 0.91</td>
</tr>
<tr>
<td>LVMI mg/g</td>
<td>1.38 ± 0.08</td>
<td>1.91 ± 0.04†</td>
<td>1.70 ± 0.04†</td>
<td>1.71 ± 0.04†</td>
</tr>
<tr>
<td>LVMI mg/mm</td>
<td>11.18 ± 0.47‡</td>
<td>14.28 ± 0.36</td>
<td>5.16 ± 0.06†</td>
<td>6.76 ± 0.91†</td>
</tr>
</tbody>
</table>

Values are means ± SE; n, no. of rats. *P < 0.05 vs. all others groups. †P < 0.05 vs. Wistar rats. ‡P < 0.05 vs. Wistar isoproterenol rats.

Fig. 4. Ena treatment prevents isoproterenol (Iso)-induced hypertrophy, CaMKII activation, and apoptosis. A: from left to right, aldosterone plasma levels, blood pressure, and the hypertrophic indexes, HW/TL and the LVMI, measured by echocardiography, from control rats, Iso, and Iso+Ena treated rats. All of the parameters show an increment in Iso-rats that is prevented by the cotreatment with Ena. B: representative echocardiographic images of the groups examined in A. C: TUNEL and DAPI photographs of the different groups and mean values of these experiments, indicating an increment in TUNEL-positive cells normalized by total DAPI-stained nuclei, only in Iso-rats. D: typical blots and average data of the proapoptotic and antiapoptotic proteins Bax and Bcl-2, respectively, the 17-kDa cleavage product of caspase-3 and TUNEL staining (Fig. 3, A and B), and in another high RAAS activity model produced after 1 mo of Iso treatment (Table 2). Moreover, the ergometric test was not different between Iso-rats and their controls (8.50 ± 0.93 vs. 8.37 ± 0.82 min). Treatment of the animals with Ena significantly decreased the aldosterone plasma levels, indicating blockade of the RAAS. Although blood pressure tended to decrease in the Ena-treated group, this decrease did not reach significance. In turn, hypertrophy present in the Iso-rats was prevented by ACE inhibition (Fig. 4, A and B, and Table 2). Consistent with the results obtained in SHR, Fig. 4, C and D, shows that apoptosis (increased TUNEL-positive cells, Bax/Bcl-2 ratio, and caspase-3 activation) and the increased CaMKII activity induced by Iso treatment (CaMKII and Thr17 site of PLN phosphorylations) were prevented by ACE inhibition with Ena.

Taken together, these results indicate that the enhancement of RAAS in SHR and Iso-rats is associated with a significant increase in CaMKII activity and apoptosis, suggesting a possible causal link between both events in vivo. It is worth noting that, despite the structural remodeling and apoptosis observed, heart function remains preserved in these rats.

CaMKII activity in high RAAS activity models is associated with ROS production and not with [Ca2+]i increases. CaMKII activation is conventionally associated with [Ca2+]i increments. Moreover, recent experiments have emphasized the importance of ROS in the activation of the kinase [see for review, Erikson et al. (10)]. We, therefore, explored [Ca2+]i handling and ROS production in an attempt to elucidate the source of CaMKII activation in our models.

We first assessed [Ca2+]i handling in isolated myocytes from both high RAAS activity models. Figure 5A shows typical superimposed records of cellular shortening and [Ca2+]i transients (CaiT) of the SHR (red traces) and their normotensive counterparts (blue traces). The average results (Fig. 5B) show that no differences were detected between both groups in contraction amplitude, CaiT, and sarcoplasmic reticulum Ca2+ content, assessed by the amplitude of the caffeine-induced CaiT. Moreover, diastolic and systolic Ca2+ did not reach significant difference between SHR and their controls. Mean values were 1.124 ± 0.059 for control vs. 1.053 ± 0.031 and 1.556 ± 0.060 for SHR, for diastolic and systolic Fura 2-AM fluorescence, respectively. Similar results were
obtained when Iso-rats were compared with their controls. As shown in Fig. 5C, there were no differences between Iso and control rats in the contraction amplitude, CaiT amplitude, or in the sarcoplasmic reticulum Ca2+ content, suggesting that global Ca2+ levels underlying each contractile cycle do not differ between the two groups. These results are in agreement with the absence of signs of cardiac dysfunction (Tables 1 and 2 and the ergometric test). The absence of difference in Ca2+ handling confirms in in vivo models our previous in vitro and ex vivo findings, where CaMKII was activated by ANG II in the absence of detectable increases in [Ca2+]i (28).

In a second set of experiments, we estimated oxidative stress by measuring O2•− generation and lipid peroxidation in SHR, Iso-rats, and their controls. Figure 6A shows the increment in O2•− generation measured by using lucigenin chemiluminescence in SHR and Iso-rats with respect to control rats. Accordingly, TBARS, used to determine lipid peroxidation, also increased in SHR and Iso-rats compared with their controls (Fig. 6B). Taken together, these results indicated that the increase in ROS that occurred after Iso treatment is upstream of CaMKII activation, and that the kinase activity is directly related to the induction of apoptosis.

DISCUSSION

ANG II has been shown to be implicated in many cellular physiological and pathological processes. In the long term, the hormone has been associated with cardiomyocyte apoptosis (27, 33, 40). Moreover, experimental evidence indicates that a critical factor in the transition from compensated to noncompensated cardiac hypertrophy is myocyte cell loss by apoptosis (1), and that the circulating levels of ANG II are increased in heart failure. It has, therefore, been proposed that increased ANG II levels may constitute one of the major triggers for cell death in the transition to heart failure (20). Interestingly, the onset of ANG II plasma or tissue increment during the development of cardiac diseases may start well ahead of the detec-
of our knowledge, the in vivo effects of enhanced RAAS at an early stage during the development of heart disease have not been previously studied.

In the present study, we used two different models of heart disease with exacerbated RAAS well before the appearance of signs or symptoms of heart failure. The main conclusions of our results are the following: 1) exacerbation of RAAS in these models is an early event necessary to activate CaMKII and to induce cardiac apoptosis; 2) CaMKII activation and cardiomyocyte loss are early signs in the maladaptive processes implicated in the transition from compensated to decompensated LV hypertrophy (13, 22); 3) activation of CaMKII occurs in vivo without detectable [Ca\(^{2+}\)] increments and is directly related to the increase in ROS and the induction of apoptosis. These results support the contention that ANG II-induced oxidative stress resets the Ca\(^{2+}\) dependence of CaMKII, as observed in our laboratory’s previous in vitro and ex vivo experiments (28).

**Animal models.** The models used are widely known as cardiac hypertrophy and failure models.

The SHR model is paradigmatic, since it mimics human essential hypertension, and several reports described that endocrine and paracrine RAAS are active (38, 45). Although a variety of factors modify aldosterone secretion, ANG II and potassium (43) are the most important regulators. Thus the increased aldosterone plasma levels found in our animals can be taken as an index of ANG II levels, as previously described (2, 45).

The Iso-induced cardiac injury model is recognized as one of the toxic cardiomyopathy models of hypertrophy and heart failure (9, 16, 34). Excessive doses of catecholamines produce diffuse myocardial destruction with myocyte loss and necrosis, as well as extensive fibrosis in animals and in patients. This kind of damage may also be seen in patients with pheochromocytoma (37). In this model, an exacerbation of RAAS was previously described (16) and confirmed by the present results.

In the present work, we used these two models of enhanced RAAS at an early stage of disease, as evident by the significant degree of hypertrophy without heart failure signs.

**The early signs of heart disease.** Typically, heart failure is the culmination of long-standing diseases, such as hypertension, ischemia from atherosclerosis, viral myocarditis, valvular insufficiency, or mutations in genes encoding sarcomeric proteins (2, 25). Besides contractile disturbances of cardiomyocytes and interstitial and perivascular fibrosis, cardiomyocyte loss is now being considered as one of the determinant factors of the maladaptive events that negatively impacts the myocardium and its propensity toward failure (12). Although the apoptotic rate observed in the present results is low, rodent studies have implicated low rates of cardiac myocyte apoptosis in the pathogenesis of heart failure. For instance, it has been previously shown that an apoptotic rate as low as 0.023% is sufficient to cause a lethal, dilated cardiomyopathy within 8–24 wk in transgenic mice with cardiac-restricted expression of an inducible caspase-8 allele (41). There is no information concerning the magnitude of cell loss required to depress cardiac contractility in the hypertrophied human heart when cell death occurs (15). Indeed, the apoptotic process takes at most 24 h to be completed, and heart failure is a condition that only manifests itself after many years. Thus it is conceivable that chronic loss of small number of cardiomyocytes on a daily
basis can have dramatic consequences on myocardial integrity (36). Moreover, myocardial apoptosis is evident in the myocardium before the occurrence of ventricular dilation and the development of symptoms, which suggests that apoptosis is a causative mechanism rather than a consequence of failure (14). The present results reveal that the increase in apoptotic death, as well as the enhanced activity of CaMKII, are early events in these and probably other models with exacerbated RAAS. Since apoptosis paralleled hypertrophy in these two models, the results may indicate that apoptosis represents either an early step in the evolution to heart failure being involved in cardiac remodeling or a mechanism tending to compensate the development of hypertrophy. Further studies are currently on course to discriminate between these possibilities.

Ca\(^{2+}\) vs. ROS and the role of CaMKII in cardiac disease. CaMKII is typically activated by increments in \([Ca^{2+}]_i\) and calmodulin (Ca\(^{2+}\)/Cam). The complex Ca\(^{2+}\)/Cam promotes a conformational change that relieves the autoinhibitory effect of the regulatory domain on the kinase, activating the enzyme. In the sustained presence of Ca\(^{2+}\)/Cam, CaMKII undergoes intersubunit autophosphorylation, resulting in Ca\(^{2+}\)/Cam-independent activity. Recent experimental evidence indicated that ROS-induced oxidation of methionine residues is able to sustain CaMKII activity in the absence of Ca\(^{2+}\)/Cam. This action requires, however, previous binding of Ca\(^{2+}\)/Cam to expose the autoinhibitory domain of CaMKII for oxidation (11). Interestingly, in a previous study, our laboratory concluded that ROS resets the dependence of CaMKII to Ca\(^{2+}\) to extremely low \([Ca^{2+}]_i\) levels (28). The present results obtained in two different in vivo models are consistent with these previous findings, since the increased activity of CaMKII occurred in the absence of any detectable increase in \([Ca^{2+}]_i\], but in the presence of a significant increase in ROS production. Our results in transgenic mice further indicate that ROS production is upstream of CaMKII activation in the cascade of events that produces apoptosis after Iso treatment. In this

![Image](image_url)
context, it is worthwhile to mention that ROS-induced phosphatase inhibition could also contribute to sustained CaMKII activation in vivo (19).

Perspectives. The present results clearly indicate that activation of CaMKII and the associated apoptosis are very early events in the development of heart disease that are evident even when the only manifestation of the injury is the presence of hypertrophy, without any sign or symptom of cardiac dysfunction. They further show that CaMKII activity and apoptosis can both be prevented by inhibition of RAAS. Whether the data can be extrapolated to humans remains to be shown. However, the apoptotic rate obtained in the present results is much lower than the one measured in cardiac tissue from patients with end-stage heart failure, suggesting that apoptosis may also be a causal mechanism of human heart failure. If so, cardiac myocyte apoptosis and CaMKII may constitute novel targets for therapies directed against heart failure. Moreover, in the context of hypertrophy and hypertension, activation of CaMKII could be considered an early index of bad prognosis.

ACKNOWLEDGMENTS

The excellent technical assistance of Andrés Pinilla in echocardiographic imaging is gratefully acknowledged. The assistance of Karina Porzio and Laura Suarez for RIA determinations is also acknowledged.

GRANTS

This work was supported by Fogarty Grant R03 TW07713 (National Institutes of Health), PICT 26171 from Agencia Nacional de Promoción Científica y Tecnológica, and PIP 2139 from Consejo Nacional de Investigaciones Científicas y Técnicas to A. Mattiazzi, and PICT 1041 from Agencia Nacional de Promoción Científica y Tecnológica to J. Palomeque.

DISCLOSURES

No conflicts of interest, financial or otherwise, are declared by the author(s).

AUTHOR CONTRIBUTIONS

J.O.V.R. and J.P. performed experiments; J.O.V.R. and J.P. analyzed data; J.O.V.R. and J.P. prepared figures; J.O.V.R., J.P., and A.M. approved final version of manuscript. They further show that CaMKII activity and apoptosis can both be prevented by inhibition of RAAS. Whether the data can be extrapolated to humans remains to be shown. However, the apoptotic rate obtained in the present results is much lower than the one measured in cardiac tissue from patients with end-stage heart failure, suggesting that apoptosis may also be a causal mechanism of human heart failure. If so, cardiac myocyte apoptosis and CaMKII may constitute novel targets for therapies directed against heart failure. Moreover, in the context of hypertrophy and hypertension, activation of CaMKII could be considered an early index of bad prognosis.

REFERENCES


of reactive oxygen species and p38 MAPK. 


